Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population

Clinical and Experimental Medicine

Volumn 11, Issue 2, 2011, Pages 75-80

  Yang, Zaixing ^a   Liang, Yan ^a   Xi, Weiqiang ^a   Li, Chang ^a   Zhong, Renqian ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Erythrocytopenia; Interleukin 33; Leukopenia; Systemic lupus erythematosus; Thrombocytopenia

Indexed keywords

AUTOANTIBODY; C REACTIVE PROTEIN; COMPLEMENT; IMMUNOGLOBULIN A; INTERLEUKIN 33; LA ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHINESE; CONTROLLED STUDY; DISEASE COURSE; ERYTHROCYTE; ERYTHROCYTE SEDIMENTATION RATE; ERYTHROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; FEMALE; HUMANS; INTERLEUKINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; SERUM; YOUNG ADULT;

EID: 79958142088     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-010-0115-4     Document Type: Article

References (36)

1. AM Fairhurst AE Wandstrat EK Wakeland 2006 Systemic lupus erythematosus: multiple immunologic phenotypes in a complex genetic disease Adv Immunol 92 1 69 17145301 10.1016/S0065-2776(06)92001-X 1:CAS:528:DC%2BD1cXhsVOqtb8%3D (Pubitemid 44828118)
2. TJ Vyse BL Kotzin 1998 Genetic susceptibility to systemic lupus erythematosus Ann Rev Immunol 16 261 292 10.1146/annurev.immunol.16.1.261 1:CAS:528:DyaK1cXislygtb0%3D (Pubitemid 28183366)
3. GC Tsokos GM Kammer 2000 Molecular aberrations in human systemic lupus erythematosus Mol Med Today 6 418 424 11074367 10.1016/S1357-4310(00)01798-6 1:CAS:528:DC%2BD3cXosFKht7Y%3D
4. A Rahman DA Isenberg 2008 Systemic lupus erythematosus N Engl J Med 358 929 939 18305268 10.1056/NEJMra071297 1:CAS:528:DC%2BD1cXisF2mtbo%3D (Pubitemid 351397092)
5. KY Su DS Pisetsky 2009 The role of extracellular DNA in autoimmunity in SLE Scand J Immunol 70 175 183 19703007 10.1111/j.1365-3083.2009.02300.x 1:CAS:528:DC%2BD1MXhtFOrurbF
6. T McAlindon 2000 Update on the epidemiology of systemic lupus erythematosus: new spins on old ideas Curr Opin Rheumatol 12 104 112 10751013 10.1097/00002281-200003000-00004 1:STN:280:DC%2BD3c3htlSltw%3D%3D (Pubitemid 30152030)
7. Novick D, Elbirt D, Miller G, Dinarello CA, Rubinstein M, Sthoeger ZM (2009) High circulating levels of free interleukin-18 in patients with active SLE in the presence of elevated levels of interleukin-18 binding protein. J Autoimmun (Epub ahead of print)
8. C Lood B Gullstrand L Truedsson AI Olin GV Alm L Ronnblom G Sturfelt ML Eloranta AA Bengtsson 2009 C1q inhibits immune complex-induced interferon-αproduction in plasmacytoid dendritic cells: a novel link between C1q deficiency and systemic lupus erythematosus pathogenesis Arthr Rheum 60 10 3081 3090 10.1002/art.24852 1:CAS:528:DC%2BD1MXhsFOmtbfJ
9. J Schmitz A Owyang E Oldham Y Song E Murphy TK McClanahan G Zurawski M Moshrefi J Qin X Li DM Gorman JF Bazan RA Kastelein 2005 IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines Immunity 23 479 490 16286016 10.1016/j.immuni.2005.09.015 1:CAS:528:DC%2BD2MXht12msr7K (Pubitemid 41587888)
10. EK Brint KA Fitzgerald P Smith AJ Colye JC Gutierrez-Ramos PG Fallon LA O'Neil 2002 Characterization of signaling pathways activated by the interleukin 1(IL-1) receptor homologue T1/ST2. A role for Jun N-terminal kinase in IL-4 induction J Biol Chem 277 49205 49211 12368275 10.1074/jbc.M209685200 1:CAS:528:DC%2BD38XpsFalur0%3D (Pubitemid 36014349)
11. V Carriere L Roussel N Ortega DA Lacorre L Americh L Aguilar G Bouche JP Girard 2007 IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo Proc Natl Acad Sci USA 104 282 287 17185418 10.1073/pnas.0606854104 1:CAS:528:DC%2BD2sXjt12msw%3D%3D (Pubitemid 46068023)
12. G Palmer D Talabot-Ayer C Lamacchia D Toy CA Seemayer S Viatte A Finckh DE Smith C Gabay 2009 Inhibition of interleukin-33 signaling attenuateds the severity of expreimental arthritis Arthr Rheum 60 3 738 749 10.1002/art.24305 1:CAS:528:DC%2BD1MXktVGmsLg%3D
13. C Gabay LB Mclnnes 2009 The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases Arthr Res Therapy 11 230 243 10.1186/ar2680
14. D Xu HR Jiang P Kewin Y Li R Mu AR Fraser N Pitman M Kurowska-Stolarska AN McKenzie IB Mclnnes FY Liew 2008 IL-33 excacerbates antigen-incduced arthritis by activating mast cells Proc Natl Acad Sci USA 105 10913 10918 18667700 10.1073/pnas.0801898105 1:CAS:528:DC%2BD1cXpvFOisrc%3D
15. AM Miller D Xu DL Asquith L Denby Y Li N Sattar AH Baker IB Mclnnes FY Liew 2008 IL-33 reduces the development of atherosclerosis J Exp Med 205 339 346 18268038 10.1084/jem.20071868 1:CAS:528:DC%2BD1cXisVeht7c%3D (Pubitemid 351281600)
16. MD Smithgall MR Comeau BR Yoon D Kaufman R Armitage DE Smith 2008 IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells Int Immunol 20 8 1019 1030 18550585 10.1093/intimm/dxn060 1:CAS:528:DC%2BD1cXptVenu7w%3D
17. S Morimoto YK Tokano H Kaneko K Nozawa H Amano H Hashimoto 2001 The increased interleukin-13 in patients with systemic lupus erythematosus: relation to other Th1-, Th2-related cytokines and clinical findings Autoimmunity 34 1 19 25 11681489 10.3109/08916930108994122 1:CAS:528:DC%2BD3MXnt1GisbY%3D (Pubitemid 32888272)
18. X Wen D Zhang Y Kikuchi Y Jiang K Nakamura Y Xiu H Tsurui K Takahashi M Abe M Ohtsuji H Nishimura K Takatsu T Shirai S Hirose 2004 Transgene-mediated hyper-expression of IL-5 inhibits autoimmune disease but increases the risk of B cell chronic lymphocytic leukemia in a model of murine lupus Eur J Immunol 34 10 2740 2749 15368290 10.1002/eji.200425267 1:CAS:528:DC%2BD2cXovVektbk%3D (Pubitemid 39430151)
19. D Gomez PA Correa LM Gomez J Cadena JF Molina JM Anaya 2004 Th1/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor a protective? Semin Arthr Rheum 33 6 404 413 10.1016/j.semarthrit.2003. 11.002 1:CAS:528:DC%2BD2cXks1ersL4%3D (Pubitemid 38887139)
20. V Pascual F Allantaz P Patel AK Palucka D Chaussabel J Banchereau 2008 How the sutdy of children with rheumatic diseases identified interferon-alpha and interliukin-1 as novel therapeutic targets Immunol Rev 223 39 59 18613829 10.1111/j.1600-065X.2008.00643.x 1:CAS:528:DC%2BD1cXptlGls78%3D (Pubitemid 351986188)
21. M Aringer JS Smolen 2004 Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention Lupus 13 5 344 347 15230290 10.1191/0961203303lu1024oa 1:CAS:528:DC%2BD2cXlvVels7w%3D (Pubitemid 38788494)
22. MC Hochberg 1997 Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter] Arthr Rheum 40 1725 10.1002/art.1780400928 1:STN:280:DyaK2svmsVaisw%3D%3D
23. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria 2006 The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials Arthr Rheum 54 421 432 10.1002/art.21625 (Pubitemid 43228616)
24. FC Arnett SM Edworthy DA Bloch DJ McShane JF Fries NS Cooper, et al. 1988 The American Rheumatism Assocaition 1987 revised criteria for the classification of rheumatoid arthritis Arthr Rhuem 31 315 324 10.1002/art.1780310302 1:STN:280:DyaL1c7pt1Ohsg%3D%3D (Pubitemid 18091653)
25. C Bombardier DD Gladman MB Urowitz D Caron DH Chang the Committee on Prognosis Studies in SLE 1992 Derivation of the SLEDAI: a disease activity index for lupus patients Arthr Rheum 35 630 640 10.1002/art.1780350606 1:STN:280:DyaK383oslWrtg%3D%3D
26. MY Mok FP Huang WK Ip Y Lo FY Wong EY Chan KF Lam D Xu 2010 Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus Rheumatology (Oxford) 49 520 527 10.1093/rheumatology/ kep402 1:CAS:528:DC%2BC3cXitFejs7c%3D [Epub ahead of print]
27. DJ McCarty S Manzi TA Medsger Jr R Ramsey-Goldman RE LaPorte CK Kwoh 1995 Incidence of systemic lupus erythematosus. Race and gender differences Arthr Rheum 38 1260 1270 10.1002/art.1780380914 1:STN:280:DyaK28%2Fhs1SmtQ%3D%3D
28. S Studenski NB Allen DS Caldwell JR Rice RP Polisson 1987 Survival in systemic lupus erythematosus. A multivariate analysis of demographic factors Arthr Rheum 30 1326 1332 10.1002/art.1780301202 1:STN:280:DyaL1c7jsVChsw%3D%3D (Pubitemid 18051903)
29. S Bematsky JF Boivin L Joseph, et al. 2006 Mortality in systemic lupus erythematosus Arthr Rheum 54 2550 2557 10.1002/art.21955 (Pubitemid 44205016)
30. EY Rhew SM Manzi AR Dyer, et al. 2009 Differences in subclinical cardiovascular disease between African American and Caucasion women with systemic lupus erythematosus Transl Res 153 51 59 19138649 10.1016/j.trsl.2008. 11.006
31. T Pecaric-Petkovic SA Didichenko S Kaempfer N Spiegl CA Dahinden 2009 Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33 Blood 113 7 1526 1534 18955562 10.1182/blood-2008-05- 157818 1:CAS:528:DC%2BD1MXitlCrtb4%3D
32. Z Allakhverdi DE Smith MR Comeau G Delespesse 2007 Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells J Immunol 179 2051 2054 17675461 1:CAS:528:DC%2BD2sXosVyrur4%3D
33. M Iikura H Suto N Kajiwara, et al. 2007 IL-33 can promote survival, adhesion and cytokine production in human mast cells Lab Invest 87 971 978 17700564 10.1038/labinvest.3700663 1:CAS:528:DC%2BD2sXhtVCrtLnK (Pubitemid 47429189)
34. SA Chung C Tian KE Taylor AT Lee WA Ortmann G Hom RR Graham J Nititham JA Kelly J Morrisey H Wu H Yin ME Alarcon-Riquelme BP Tsao JB Harley PM Gaffney KL Moser S Manzi M Petri PK Gregersen CD Langefeld TW Behrens MF Seldin LA Criswell 2009 European population substructure is associated with mucocutaneous manifestations and autoantibody production in systemic lupus erythematosus Arthr Rheum 60 8 2448 2456 10.1002/art.24707
35. M Samarkos KA Davies C Gordon S Loizou 2006 Clinical significance of IgA anticardiolipin and anti-β2-GP1 antibodies in patients with systemic lupus erythematosus and primary antiphosphlipid syndrome Clin Rheumatol 25 199 204 16091839 10.1007/s10067-005-1156-z 1:STN:280:DC%2BD287jvFCqug%3D%3D (Pubitemid 43372318)
36. C Chen K Lin S Lin W Tsai J Yen S Chang S Lu H Liu 2005 High prevalence of immunoglobulin A antibody against Epstein-Barr virus capsid antigen in adult patients with lupus with disease flare: case control studies J Rheumatol 32 44 47 15630723 (Pubitemid 40092589)